Global Anti Infective Vaccines Market Size By Type (Inactivated Vaccines, Conjugate Vaccines), By Application (Bacterial Diseases, Viral Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Anti-Infective Vaccines Market was valued at USD 45.7 billion in 2023 and is projected to reach USD 83.4 billion by 2031, growing at a CAGR of 7.6% during the forecast period (2023–2031). This market is driven by the increasing prevalence of infectious diseases, rising global immunization programs, and robust investments in vaccine R&D. Governments and health organizations worldwide are focusing on the prevention of infectious diseases through vaccination, especially in the wake of the COVID-19 pandemic, which has significantly heightened public awareness around immunization and disease prevention.

Drivers:

1. Growing Prevalence of Infectious Diseases:

Outbreaks of diseases such as influenza, HPV, hepatitis, and meningitis are intensifying the need for preventive vaccines. This rising incidence rate is pushing healthcare authorities to adopt broad immunization strategies.

2. Expanding Immunization Initiatives:

Organizations like WHO, GAVI, and UNICEF are collaborating with governments to expand vaccine accessibility. Programs targeting infant immunization and school-based vaccinations are creating consistent demand.

3. Technological Advancements in Vaccine Development:

Innovations such as mRNA platforms, viral vector technologies, and protein subunit vaccines are enhancing vaccine efficacy and reducing development time, thereby accelerating new product launches.

Restraints:

1. High Cost of Development and Storage:

Vaccine R&D and clinical trials require substantial investment, and some anti-infective vaccines need ultra-cold chain storage, posing logistical challenges especially in low-income regions.

2. Vaccine Hesitancy:

Misinformation, cultural beliefs, and concerns about side effects contribute to public resistance against vaccines in several regions, limiting full-scale market penetration.

Opportunity:

1. Expansion into Emerging Markets:

Asia-Pacific, Africa, and Latin America are experiencing a rapid increase in healthcare spending and awareness. These regions offer immense growth potential for anti-infective vaccine manufacturers.

2. Development of Multivalent and Combination Vaccines:

The demand for multivalent vaccines (protecting against multiple infections with a single dose) is increasing, offering cost-efficiency and better compliance, especially in pediatric populations.

3. Integration of AI in Vaccine Research:

Artificial intelligence and big data analytics are revolutionizing vaccine discovery and clinical trial efficiency, accelerating time-to-market and reducing costs.

Market by System Type Insights:

By vaccine type, the Live Attenuated Vaccines segment accounted for the largest market share in 2023. These vaccines offer robust and long-lasting immunity and are commonly used for diseases like measles, mumps, rubella, and tuberculosis. Meanwhile, the mRNA-based Vaccines segment is witnessing the fastest growth, propelled by the success of COVID-19 vaccines and the ongoing investment in mRNA platforms for broader applications.

Market by End-use Insights:

The Pediatric segment dominated the market in 2023, driven by strong government-backed childhood immunization programs. However, the Adult segment is expected to grow significantly, fueled by increasing demand for seasonal flu, HPV, and travel-related vaccines.

Market by Regional Insights:

North America held the largest market share in 2023 due to high healthcare expenditure, robust immunization coverage, and technological innovation. Asia-Pacific is poised for the highest growth rate during the forecast period, supported by rising awareness, expanding healthcare infrastructure, and growing investments in local vaccine production.

Competitive Scenario:

Key players in the Global Anti-Infective Vaccines Market include GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Moderna Inc., CSL Limited, Bharat Biotech, Serum Institute of India, and AstraZeneca plc. These companies are actively engaged in strategic collaborations, expanding manufacturing capabilities, and launching new products to stay competitive.

Key Market Developments:

In 2024, Pfizer Inc. received FDA approval for its combined RSV and influenza vaccine targeting adults aged 60 and above.

In 2023, Moderna initiated trials for a new mRNA-based HIV vaccine.

Serum Institute of India expanded its global footprint by establishing manufacturing hubs in Africa and Southeast Asia in 2023.

Scope of Work – Global Anti-Infective Vaccines Market

FAQs:

1. What is the current market size of the Global Anti-Infective Vaccines Market?

The market size was valued at USD 45.7 billion in 2023.

2. What is the major growth driver of the Global Anti-Infective Vaccines Market?

The major driver is the increasing prevalence of infectious diseases and the expansion of global immunization initiatives.

3. Which is the largest region during the forecast period in the Global Anti-Infective Vaccines Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow fastest.

4. Which segment accounted for the largest market share in the Global Anti-Infective Vaccines Market?

The Live Attenuated Vaccines segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Anti-Infective Vaccines Market?

Key players include Pfizer, GSK, Sanofi, Moderna, Johnson & Johnson, Merck, CSL, Serum Institute, Bharat Biotech, and AstraZeneca.